Progyny (NASDAQ:PGNY) Upgraded at BTIG Research

Progyny (NASDAQ:PGNY) was upgraded by equities research analysts at BTIG Research from a “neutral” rating to a “buy” rating in a research report issued on Monday,Benzinga reports. The brokerage currently has a $28.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 24.41% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Bank of America raised their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Canaccord Genuity Group lifted their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Trading Up 2.8 %

NASDAQ:PGNY traded up $0.61 on Monday, hitting $22.51. The company’s stock had a trading volume of 301,087 shares, compared to its average volume of 1,690,863. Progyny has a one year low of $13.39 and a one year high of $37.92. The stock has a fifty day moving average of $22.06 and a two-hundred day moving average of $18.50. The firm has a market capitalization of $1.92 billion, a P/E ratio of 38.80, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Hedge Funds Weigh In On Progyny

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PGNY. Signaturefd LLC grew its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after buying an additional 1,246 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares during the period. Caitlin John LLC raised its position in Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock worth $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, Natixis acquired a new position in Progyny during the 4th quarter worth about $69,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.